GLP-26
Based on 2 publication(s) in Google Scholar
GLP-26 is a HBV capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC50=3 nM), and reduces cccDNA by >90% at 1 μM. GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools. GLP-26 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.36%
- CAS 番号: 2133017-36-2
- 分子式: C19H17F2N3O3
- 分子量:373.35
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
MedChemExpress(MCE)の使用を引用している文献 GLP-26
More
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | CC50 |
>100 μM
Compound: 5; GLP-26
|
Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915] |
| Hepatocyte | CC50 |
>10 μM
Compound: 36; GLP-26
|
Cytotoxicity in human primary hepatocytes
Cytotoxicity in human primary hepatocytes
|
[PMID: 32949990] |
| HepG2 | CC50 |
>100 μM
Compound: 5; GLP-26
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915] |
| PBMC | CC50 |
>100 μM
Compound: 5; GLP-26
|
Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915] |
| Vero | CC50 |
46.4 μM
Compound: 5; GLP-26
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915] |
GLP-26 (0.7-1.7 μM; 3 days) reduces secreted HBeAg in HepNTCP-DL cells transfected with HBV wild type, with EC50 values of 0.7 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepNTCP-DL cells
-
Concentration:0.7-1.7 μM
-
Incubation Time:3 days
-
Result:Reduced secreted HBeAg in HepNTCP-DL cells.
化学情報
-
CAS 番号 2133017-36-2
-
性状 Solid
-
分子量 373.35
-
分子式 C19H17F2N3O3
-
Color Light yellow to brown
-
SMILES
O=C(C1=C(C)C(C(C(NCC#C)=O)=O)=C(C)N1C)NC2=CC=C(F)C(F)=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
PLoS Pathog
HBV capsid assembly modulators differentially modulate the assembly of wild-type and drug-resistant core protein chimeric nucleocapsids and empty capsids. [Abstract]2025 Aug 5;21(8):e1013391. PMID: 40763308 -
Viruses
2022 Jan 18;14(2):174. PMID: 35215767
溶剤 & 溶解度
DMSO : 125 mg/mL (334.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6785 mL | 13.3923 mL | 26.7845 mL | 66.9613 mL |
| 5 mM | 0.5357 mL | 2.6785 mL | 5.3569 mL | 13.3923 mL | |
| 10 mM | 0.2678 mL | 1.3392 mL | 2.6785 mL | 6.6961 mL | |
| 15 mM | 0.1786 mL | 0.8928 mL | 1.7856 mL | 4.4641 mL | |
| 20 mM | 0.1339 mL | 0.6696 mL | 1.3392 mL | 3.3481 mL | |
| 25 mM | 0.1071 mL | 0.5357 mL | 1.0714 mL | 2.6785 mL | |
| 30 mM | 0.0893 mL | 0.4464 mL | 0.8928 mL | 2.2320 mL | |
| 40 mM | 0.0670 mL | 0.3348 mL | 0.6696 mL | 1.6740 mL | |
| 50 mM | 0.0536 mL | 0.2678 mL | 0.5357 mL | 1.3392 mL | |
| 60 mM | 0.0446 mL | 0.2232 mL | 0.4464 mL | 1.1160 mL | |
| 80 mM | 0.0335 mL | 0.1674 mL | 0.3348 mL | 0.8370 mL | |
| 100 mM | 0.0268 mL | 0.1339 mL | 0.2678 mL | 0.6696 mL |